Evidence map›Paper›PMID 39417408›Full record

Observational studyAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Investigating the feasibility of

Anna Lavrova, Ryota Satoh, Nha Trang Thu Pham, Aivi Nguyen, Clifford R Jack, Ronald C Petersen, Reichard R Ross, Dennis W Dickson, Val J Lowe, Jennifer L Whitwell and 1 more

Abstract readObservational Study
In one paragraph

Observational study in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Primary age-related tauopathy.Acta neuropathologica · 2025
    Review
  3. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
  5. Investigating the feasibility ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna LavrovaDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0009-0001-7521-7082
Ryota SatohDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Nha Trang Thu PhamDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Aivi NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Reichard R RossDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
The neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9M
Longitudinal multi-modal imaging in progressive supranuclear palsy syndromesR37NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Jennifer Louise Whitwell · 2026 to 2026
$3.7M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseRF1NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2021 to 2021
$1.2M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseR01NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2024 to 2025
$767k
Elsie and Marvin Dekelboum Family FoundationNIA NIH HHS P30 AG062677NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG037491NIA NIH HHS R01 AG050603NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NIDCD NIH HHS R01 DC012519NIDCD NIH HHS R01 DC014942NIH HHS P30-AG062677NIH HHS R01-AG37491NIH HHS R01-AG50603NIH HHS R01-DC12519NIH HHS R01-DC14942NIH HHS R01-NS89757NIH HHS R37-AG11378NIH HHS RF1-NS112153NIH HHS U01-AG006786NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS112153NINDS NIH HHS R37 NS089757NINDS NIH HHS RF1 NS112153Oxley Foundation
6 · The paper itself

Abstract

introductionPrimary age-related tauopathy (PART) is characterized by neurofibrillary tangles and minimal β-amyloid deposition, diagnosed postmortem. This study investigates

methodsWe analyzed FTP PET scans from 50 autopsy-confirmed PART and 13 control subjects. Temporal lobe uptake was assessed both qualitatively and quantitatively. Demographic and clinicopathological characteristics and voxel-level uptake using SPM12 were compared between FTP-positive and FTP-negative cases. Intra-reader reproducibility was evaluated with Krippendorff's alpha.

resultsMinimal/mild and moderate FTP uptake was seen in 32% of PART cases and 62% of controls, primarily in the left inferior temporal lobe. No demographic or clinicopathological differences were found between FTP-positive and FTP-negative cases. High intra-reader reproducibility (α = 0.83) was noted. DISCUSSION: FTP PET imaging did not show a specific uptake pattern for PART diagnosis, indicating that in vivo PART identification using FTP PET is challenging. Similar uptake in controls suggests non-specific uptake in PART. HIGHLIGHTS:

Indexed as

CarbolinesFeasibility StudiesPositron-Emission TomographyTauopathiesAgedAged, 80 and overBrainFemaleHumansMaleMiddle AgedRadiopharmaceuticalsReproducibility of ResultsTemporal Lobe7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinesRadiopharmaceuticals18F‐flortaucipir PETdefinite PARTPARTprimary age‐related tauopathytau‐PET

Identifiers

PMID39417408
PMCPMC11667508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.